MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 525721 | Name: Muzolimine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Muzolimine is pyrazole diuretic with long duration and high capacity of action. It was proposed for kidney failure and hypertension but was withdrawn worldwide because of severe neurological effects.

Chemical Structure

Muzolimine
Muzolimine
CAS#55294-15-0

Theoretical Analysis

MedKoo Cat#: 525721

Name: Muzolimine

CAS#: 55294-15-0

Chemical Formula: C11H11Cl2N3O

Exact Mass: 271.0279

Molecular Weight: 272.13

Elemental Analysis: C, 48.55; H, 4.07; Cl, 26.06; N, 15.44; O, 5.88

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Muzolimina; Muzoliminum; Edrul; Muzolimine
IUPAC/Chemical Name
3-amino-1-(1-(3,4-dichlorophenyl)ethyl)-1H-pyrazol-5(4H)-one
InChi Key
RLWRMIYXDPXIEX-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H11Cl2N3O/c1-6(16-11(17)5-10(14)15-16)7-2-3-8(12)9(13)4-7/h2-4,6H,5H2,1H3,(H2,14,15)
SMILES Code
O=C1CC(N)=NN1C(C)C2=CC=C(Cl)C(Cl)=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 272.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Grima M, Michel B, Barthelmebs M, Stephan D, Imbs JL. The effects of muzolimine and urine from muzolimine-treated rats on Na+K+Cl- cotransport in Madin-Darby canine kidney cells. Eur J Pharmacol. 1991 Sep 17;202(2):137-42. PubMed PMID: 1802742. 2: Pohlmann-Eden B, Berlit P, Maibach EA, Gretz N. Muzolimine-induced severe neuromyeloencephalopathy: report of seven cases. Acta Neurol Scand. 1991 Jan;83(1):41-4. PubMed PMID: 1849334. 3: Sastry CS, Suryanarayana MV, Tipirneni AS, Prasad TN. Spectrophotometric determination of muzolimine. Talanta. 1988 Nov;35(11):914-6. PubMed PMID: 18964644. 4: Planelles G, Meilhac B, Anagnostopoulos T. Effects of muzolimine on the late distal tubule of necturus kidney. J Pharmacol Exp Ther. 1988 Sep;246(3):1152-7. PubMed PMID: 3418514. 5: Tartagni F, Ortolani P, Degli Esposti D, Cervi V, Magnani B. [Effects of sequentially administered or combined muzolimine and furosemide on water and solute excretion: quantitative and qualitative aspects]. Recenti Prog Med. 1987 Nov;78(11):496-9. Italian. PubMed PMID: 3324236. 6: Pohlmann-Eden B, Berlit P, Bangert J, Gretz N. [Neuromyelopathy caused by treatment with muzolimine]. Dtsch Med Wochenschr. 1987 Jul 31;112(31-32):1238. German. PubMed PMID: 3608851. 7: Galletti F, Strazzullo P, Gagliardi R, Cirillo M, Siani A, Iacone R, Mancini M. Metabolic effects of long-term therapy with muzolimine and chlorthalidone in hypertension. Eur J Clin Pharmacol. 1987;33(5):515-7. PubMed PMID: 3428346. 8: Salerno L, Pepe S, Sallì L, Scalici G, Curiale B, Salvato F. [Muzolimine in liver cirrhosis and essential arterial hypertension]. Clin Ter. 1986 Jul 31;118(2):99-107. Italian. PubMed PMID: 3742982. 9: Licata G, Scaglione R, Parrinello G, Rini GB, Asta N. [Clinical and hemodynamic effects of medium-term treatment with muzolimine in subjects with essential arterial hypertension]. G Ital Cardiol. 1986 Jul;16(7):583-5. Italian. PubMed PMID: 3781147. 10: Geck P, Pfeiffer B. Inhibition of ion transport in Ehrlich cells by muzolimine. Naunyn Schmiedebergs Arch Pharmacol. 1986 Jul;333(3):323-9. PubMed PMID: 2429195. 11: Hannedouche T, Fillastre JP. [Success of muzolimine in the treatment of refractory edema syndromes]. Presse Med. 1986 Apr 26;15(17):802. French. PubMed PMID: 2940531. 12: Malatino LS, Fiore CE, Foti R, Greco G, Fargetta C, Tamburino G. Slow-release nifedipine associated with muzolimine in the treatment of mild to moderate essential hypertension. Am J Nephrol. 1986;6 Suppl 1:108-10. PubMed PMID: 3826145. 13: Bazzato G, Coli U, Landini S, Fracasso A, Righetto F, Scanferla F, Forte M, Morachiello P. Muzolimine vs. furosemide in nephrotic syndrome: further support of different carrier(s) operating for enteral absorption. Z Kardiol. 1985;74 Suppl 2:92-5. PubMed PMID: 4002811. 14: Bandiani G, Camaiora E, Nicolini MA, Perotta U. Muzolimine in patients on chronic hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD). Z Kardiol. 1985;74 Suppl 2:84-7. PubMed PMID: 4002809. 15: Kirsten R, Molz KH, Tzonev I, Nelson K. Clinical evaluation of muzolimine and indapamide during treatment for essential hypertension. Z Kardiol. 1985;74 Suppl 2:66-72. PubMed PMID: 4002807. 16: Beneitez C. Muzolimine in the treatment of essential arterial hypertension not controlled with other antihypertensive drugs. Z Kardiol. 1985;74 Suppl 2:52-5. PubMed PMID: 4002805. 17: Verma SP, Taylor SH. Haemodynamic studies with muzolimine in left ventricular failure complicating acute myocardial infarction. Z Kardiol. 1985;74 Suppl 2:37-42. PubMed PMID: 4002803. 18: Salerno M, Di Salvo M, Furnari R, Vaccaro F, Licciardi S, Finocchiaro S. Comparison of muzolimine and furosemide in heart failure. Z Kardiol. 1985;74 Suppl 2:32-3. PubMed PMID: 4002801. 19: Kahles H, Ertl G, Riegger G, Liebau G, Kochsiek K. Muzolimine therapy in patients with congestive heart failure in comparison with furosemide pretreatment. Effect on digoxin plasma concentration. Z Kardiol. 1985;74 Suppl 2:24-6. PubMed PMID: 4002799. 20: Garthoff B. Beneficial effect of muzolimine in postischemic acute renal failure in rats. Z Kardiol. 1985;74 Suppl 2:171-4. PubMed PMID: 4002795.